Literature DB >> 9028742

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

C Veyrat-Follet1, R Farinotti, J L Palmer.   

Abstract

The physiology of emesis has been studied for several hundred years, focusing on the different centres involved and the mechanics of expulsion. The vomiting centre receives inputs from various emetic detectors such as the gut, the vestibular labyrinths and the chemoreceptor trigger zone. Emesis is a common disabling effect in motion sickness, postoperative conditions and in radio- and chemotherapy. Our current understanding of the mechanisms has been provided mainly by the recent introduction of serotonin 5-HT3 receptor antagonists into therapeutic use. Nevertheless, despite the considerable advances made in the understanding of the different pathways involved in emesis, there are number of areas that still require experimental investigation. Different animal and human models are available to study the physiology of emesis and to evaluate the antiemetic activity of new compounds, but they need to be predictors of clinical situations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028742     DOI: 10.2165/00003495-199753020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  118 in total

Review 1.  Pharmacological agents affecting emesis. A review (Part I).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 2.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting.

Authors:  R A Leslie; Y Shah; M Thejomayen; K M Murphy; H A Robertson
Journal:  Can J Physiol Pharmacol       Date:  1990-02       Impact factor: 2.273

Review 4.  Do humoral factors mediate cancer chemotherapy-induced emesis?

Authors:  P L Carl; L X Cubeddu; C Lindley; R D Myers; A H Rezvani
Journal:  Drug Metab Rev       Date:  1989       Impact factor: 4.518

Review 5.  Neural mechanisms of emesis.

Authors:  D O Carpenter
Journal:  Can J Physiol Pharmacol       Date:  1990-02       Impact factor: 2.273

6.  Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.

Authors:  L X Cubeddu; I S Hoffmann
Journal:  J Clin Pharmacol       Date:  1993-08       Impact factor: 3.126

7.  Discrete lesions of the area postrema abolish radiation-induced emesis in the dog.

Authors:  R K Harding; H Hugenholtz; M Keaney; J Kucharczyk
Journal:  Neurosci Lett       Date:  1985-01-07       Impact factor: 3.046

8.  The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride.

Authors:  W L Smith; E M Callaham; R S Alphin
Journal:  J Pharm Pharmacol       Date:  1988-02       Impact factor: 3.765

9.  Pharyngeal, esophageal, and proximal gastric responses associated with vomiting.

Authors:  I M Lang; S K Sarna; W J Dodds
Journal:  Am J Physiol       Date:  1993-11

10.  Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.

Authors:  J D Hainsworth; G A Omura; A Khojasteh; J C Bryson; A L Finn
Journal:  Am J Clin Oncol       Date:  1991-08       Impact factor: 2.339

View more
  17 in total

Review 1.  Ondansetron: a review of its use as an antiemetic in children.

Authors:  C R Culy; N Bhana; G L Plosker
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites.

Authors:  M L López-Rodríguez; M J Morcillo; B Benhamú; M L Rosado
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

Review 3.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

Authors:  R E Gregory; D S Ettinger
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

4.  Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.

Authors:  Gerald M Higa; Miklos L Auber; Gerry Hobbs
Journal:  Support Care Cancer       Date:  2012-02-14       Impact factor: 3.603

Review 5.  Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva).

Authors:  Andrew P Ray; Seetha Chebolu; Nissar A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2009-08-21       Impact factor: 3.533

7.  Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.

Authors:  Nissar A Darmani; Yaozhi Wang; Joseph Abad; Andrew P Ray; Gerald R Thrush; Juan Ramirez
Journal:  Brain Res       Date:  2008-04-09       Impact factor: 3.252

8.  Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.

Authors:  Andrew P Ray; Seetha Chebolu; Juan Ramirez; Nissar A Darmani
Journal:  Behav Neurosci       Date:  2009-06       Impact factor: 1.912

9.  Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

Authors:  Nissar A Darmani; Jano J Janoyan; Jennifer Crim; Juan Ramirez
Journal:  Eur J Pharmacol       Date:  2007-02-16       Impact factor: 4.432

10.  The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.

Authors:  Yaozhi Wang; Andrew P Ray; Bryan A McClanahan; Nissar A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2008-08-09       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.